Peptide Schedule

Semaglutide Dosage Calculator

Weight LossInjectionFDA Approved~7 days half-life

Semaglutide is a GLP-1 receptor agonist — the same active ingredient in Ozempic and Wegovy.

Proven 15-17% body weight loss in clinical trialsSuppresses appetite at the brain levelImproves blood sugar and insulin sensitivityReduces cardiovascular risk

250mcg · Weekly

100500
10.0 units
100 units (1mL)
Concentration
2,500
mcg/mL
Draw Volume
0.100
mL
Syringe Units
10.0
units
Doses / Vial
20
doses

Summary: Add 2mL BAC water to your 5mg vial. Draw to 10.0 units on a U-100 syringe for a 250mcg dose. This vial will last 20 doses.

Cycle Planner

Subcutaneous. Typical beginner frequency: weekly.

Semaglutide Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~7 days
50%25%12.5%100%75%50%25%0%07d14d21d28d35dTime after injectionDose remaining
After 1 half-life (7d): 50% remainsAfter 2 half-lives (14d): 25% remainsAfter 3 half-lives (21d): 12.5% remains
At a 500mcg dose: 50% = 250mcg remaining after 7d. Recommended frequency: Weekly.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Semaglutide Dosing Protocol

LevelDose / InjectionFrequency
Beginner250mcgWeekly
Moderate500mcgWeekly
Aggressive1mgWeekly

Note: Titrate slowly over 4-week intervals to manage GI side effects. Start at 250mcg/week and increase by 250mcg every 4 weeks. Do not exceed 2400mcg/week.

About Semaglutide

Semaglutide is a GLP-1 receptor agonist — the same active ingredient in Ozempic and Wegovy. It mimics the hormone GLP-1, which regulates appetite and blood sugar. By slowing gastric emptying and acting on brain satiety centers, it dramatically reduces hunger and caloric intake. FDA-approved for both type 2 diabetes and obesity.

Frequently Asked Questions